Human immunoglobulin G
- Generic Name
- Human immunoglobulin G
- Brand Names
- Asceniv, Bivigam, Cuvitru, Flebogamma, Gamastan, Gammagard, Gammaked, Gammaplex, Gamunex, Hizentra, Hyqvia 5 G / 50 Ml Kit, Igivnex, Kiovig, Octagam, Panzyga, Privigen, Xembify, HyQvia, Flebogamma DIF (previously Flebogammadif)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-58-5
- Unique Ingredient Identifier
- 66Y330CJHS
- Background
Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human ...
- Indication
Human immunoglobulin G is indicated for the following conditions:
- Associated Conditions
- Acute Idiopathic Thrombocytopenic Purpura, Bacterial Infections, Chronic Idiopathic Thrombocytopenic Purpura, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Coronary Artery Aneurysm, Dermatomyositis (DM), Hepatitis A, Measles, Multifocal Motor Neuropathy (MMN), Primary humoral immunodeficiency, Rubella, Secondary humoral immunodeficiency, Varicella
- Associated Therapies
- Maintenance therapy
Polyvalent Immunoglobulin in COVID-19 Related ARds
- Conditions
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Centre Hospitalier St Anne
- Target Recruit Count
- 146
- Registration Number
- NCT04350580
- Locations
- 🇫🇷
CH Aulnay, Aulnay-sous-Bois, France
🇫🇷Hopital de Vannes, Vannes, France
🇫🇷Hopital d'instruction des armées Percy, Clamart, France
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 23
- Registration Number
- NCT04175522
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
- Conditions
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 126
- Registration Number
- NCT04044690
- Locations
- 🇺🇸
8401210 - University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇯🇵3920125 - Tokyo Medical And Dental University Medical Hospital, Bunkyo, Tokyo, Japan
🇲🇽4840081 - Centro Integral en Reumatologia, SA de CV, Guadalajara, Jalisco, Mexico
Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease
- Conditions
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 45
- Registration Number
- NCT04003844
- Locations
- 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷Kyung Hee University Medical Center, Seoul, Korea, Republic of
🇰🇷The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 6
- Registration Number
- NCT03866798
- Locations
- 🇺🇸
Octapharma Research Site, Houston, Texas, United States
Ig PRx in AECOPD: Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 48
- Registration Number
- NCT02690038
- Locations
- 🇨🇦
The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2019-10-01
- Target Recruit Count
- 30
- Registration Number
- NCT01854827
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Children's Hospital at Pittsburgh, Pittsburgh, Pennsylvania, United States
Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2012-09-20
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 45
- Registration Number
- NCT01524939
- Locations
- 🇰🇷
Seoul ST. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Kyung Hee university medical center, Seoul, Korea, Republic of
🇰🇷Kyung Hee university at Gangdong, Seoul, Korea, Republic of
GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2013-04-30
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 214
- Registration Number
- NCT01315496
- Locations
- 🇰🇷
Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of
🇰🇷Gyrongsang National University Hospital, Jinju-si, Gyeongsangnam-do,, Korea, Republic of
🇰🇷Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of
Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
- Conditions
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 9
- Registration Number
- NCT00750867
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.